Living with serious chronic diseases
At Sigilon, we are committed to discovering and developing functional cures for patients with a wide range of chronic diseases. Depending on the disease, this could mean the difference between life-long transfusions or injections, for example, and a safe, long-lasting therapy that delivers controlled doses of therapy.
We believe that the patient voice is key to driving innovation and focus on understanding the unique needs of our patient communities–applying our learnings to our research and development strategy. We value your input as we work to advance our Shielded Living Therapeutics™ platform and investigational therapies with the potential to deliver sustained levels of proteins (factors, enzymes and other molecules) that are deficient in rare blood disorders, such as hemophilia A, and lysosomal diseases, such as MPS-1. These therapies are designed to eliminate the need for frequent, life-long infusions or injections of factors or enzymes, while eliminating the peaks and troughs that result from current standard treatment regimens.
We have also applied our technology to engineer cells that have the potential to respond to the body’s changing environment and needs. For example, we are advancing several product candidates designed to release variable levels of hormones, such as insulin. By providing insulin in response to increased glucose levels, this approach could be used as a potential treatment for type 1 Diabetes, potentially freeing patients from constant disease management.
Learn how our investigational therapies work
Our investigational therapies start with human cells engineered to produce therapeutic molecules that may be missing or deficient in the body, including proteins, antibodies and hormones.
We then put the cells into tiny spheres, which were designed to do two things:
- Shield the cells from an immune response
- Allow the inflow of nutrients and outflow of a specific therapy
Here’s what a potential dose could look like. For purposes of this visualization, we have colored the spheres blue, but in reality, they are clear.
For our clinical studies, a doctor will place the spheres into the patient’s abdomen via a minimally invasive procedure. The cells are designed to live where they are placed, producing the specific protein the patient needs, which can then circulate throughout the body.
We believe that a single dose of our SLTx product candidates may provide a meaningful long-term clinical benefit to patients, and our technology allows us to re-dose, if necessary.